Renovaro Biosciences Ratios and Metrics

Market cap in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Year	Current	2023	2022	2021	2020	2019	2018	2017
Market Capitalization	210	33	102	238	196	175	-	-
Market Cap Growth	-	-67.69%	-56.98%	21.35%	12.15%	-	-	-
Enterprise Value	217	37	100	224	195	162	-16	-2
PE Ratio	-5.13	-0.83	-0.90	-8.89	-17.15	-9.69	-	-
PB Ratio	4.84	0.71	1.41	1.36	1.18	1.01	-	-
P/FCF Ratio	-18.32	-2.80	-6.49	-11.50	-18.39	-18.92	-	-
P/OCF Ratio	-18.40	-2.80	-6.50	-11.53	-18.72	-20.52	-	-
EV/EBITDA Ratio	-5.40	-0.94	-0.89	-8.51	-17.78	-9.04	2.49	0.86
EV/EBIT Ratio	-5.39	-0.94	-0.88	-8.47	-17.21	-9.01	2.48	0.85
EV/FCF Ratio	-18.85	-3.11	-6.36	-10.85	-18.29	-17.59	3.57	1.58
Debt / Equity Ratio	0.17	0.12	0.10	0.04	0.05	-	-	1.36
Debt / EBITDA Ratio	-0.18	-0.14	-0.06	-0.28	-0.69	-	-	-0.96
Debt / FCF Ratio	-0.64	-0.47	-0.45	-0.35	-0.71	-	-	-1.77
Quick Ratio	0.10	0.17	1.42	10.96	6.52	11.08	18.00	1.39
Current Ratio	0.18	0.23	1.48	11.08	6.70	11.25	18.04	1.41
Interest Coverage	-47.24	-67.38	-303.24	-69.73	-108.48	-418986.91	-43.84	-83.07
Return on Equity (ROE)	-81.30%	-63.50%	-80.10%	-16.10%	-6.70%	-11.60%	-7.90%	-
Return on Assets (ROA)	-65.30%	-52.80%	-71.80%	-15.00%	-6.40%	-10.30%	-6.70%	-
Return on Capital (ROIC)	-78.75%	-74.01%	-145.76%	-12.86%	-6.86%	-6.35%	-3.36%	-66.26%
Earnings Yield	-19.52%	-120.17%	-111.00%	-11.25%	-5.83%	-10.32%	-	-
FCF Yield	-5.46%	-35.75%	-15.40%	-8.70%	-5.44%	-5.28%	-	-
Buyback Yield / Dilution	-18.63%	-7.11%	-11.37%	-1.81%	-23.38%	-71.15%	-78.87%	-
Total Shareholder Return	-18.63%	-7.11%	-11.37%	-1.81%	-23.38%	-71.15%	-78.87%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).